MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has announced its participation in the prestigious Alzheimer’s Association International Conference (AAIC) 2025. The global event, set to take place from July 27–31 in Toronto, Canada, provides a platform for the world’s leading dementia researchers and clinicians to share the latest advancements in the field.
At the conference, Annovis Bio will present four scientific posters focused on its lead drug candidate, buntanetap. These presentations will provide updates on the company’s Alzheimer’s clinical programs and new pharmacokinetic data that highlight the drug’s potential benefits for patients with early Alzheimer’s disease.
The Four Scientific Posters Include:
- Poster #1: Design of Phase III Study Testing Buntanetap Efficacy in Early Alzheimer’s Patients
Presenter: Cheng Fang, Ph.D., Senior Vice President, Research & Development. - Poster #2: A Dual 6-Month & 18-Month Prospective, Randomized, Placebo-Controlled, Double-Blind, Pivotal Clinical Trial Evaluating Buntanetap’s Efficacy and Safety
Presenter: Sarah MacCallum, Director of Clinical Operations. - Poster #3: Advancing Buntanetap’s Development with Comparative Pharmacokinetic Characterization from Semi-Crystalline to Crystalline Forms in Animals and Humans
Presenter: Alexander Morin, Ph.D., Director of Strategic Communications. - Poster #4: Pharmacokinetic Characterization of Buntanetap in Plasma of Patients with Early Alzheimer’s and Parkinson’s Diseases
Presenter: Matthew Peterson, Ph.D., Senior Clinical Scientist.
The conference draws experts from around the globe to share breakthroughs in the diagnosis, treatment, and care of Alzheimer’s disease and related dementias. Annovis Bio’s participation underscores its commitment to leading advancements in therapies for neurodegenerative conditions.
Buntanetap, the company’s key investigational drug, aims to inhibit the formation of neurotoxic proteins known to accelerate these diseases. The posters will present not only efficacy-focused clinical designs but also pharmacokinetic data supporting its continued development.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.